Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus CHILDREN S ZYRTEC ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus CHILDREN S ZYRTEC ALLERGY.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES vs CHILDREN'S ZYRTEC ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a peripheral H1-receptor antagonist that selectively inhibits histamine-mediated effects on H1 receptors, reducing allergic symptoms. It does not penetrate the blood-brain barrier significantly, minimizing sedation.
Cetirizine is a selective antagonist of peripheral H1 histamine receptors, inhibiting histamine-mediated allergic and inflammatory responses.
Adults and children 12 years and older: 180 mg orally once daily or 60 mg orally twice daily.
5 mg (1 tablet or 5 mL oral solution) once daily; dosing frequency may be increased to 10 mg once daily (2 tablets or 10 mL) for more severe symptoms.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–15 hours) in healthy adults. This supports once-daily dosing. Half-life may be prolonged in patients with renal impairment (up to 19 hours).
Terminal half-life 8.5–10.5 hours in children 2–5 years; 9–11 hours in children 6–12 years; 8–9 hours in adults. Clinically, supports once-daily dosing.
Fexofenadine is primarily excreted unchanged in feces (approximately 80%) via biliary elimination, with minimal renal excretion (approximately 11%). It is not metabolized by the liver.
Primarily renal (60% unchanged) via tubular secretion; 40% metabolized in liver to inactive metabolites excreted in urine; <1% fecal.
Category A/B
Category C
Antihistamine
Antihistamine